BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17372897)

  • 1. Defective antitumor responses in CX3CR1-deficient mice.
    Yu YR; Fong AM; Combadiere C; Gao JL; Murphy PM; Patel DD
    Int J Cancer; 2007 Jul; 121(2):316-22. PubMed ID: 17372897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CX3CR1 regulates the maintenance of KLRG1+ NK cells into the bone marrow by promoting their entry into circulation.
    Ponzetta A; Sciumè G; Benigni G; Antonangeli F; Morrone S; Santoni A; Bernardini G
    J Immunol; 2013 Dec; 191(11):5684-94. PubMed ID: 24184559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eotaxin-3/CC chemokine ligand 26 is a functional ligand for CX3CR1.
    Nakayama T; Watanabe Y; Oiso N; Higuchi T; Shigeta A; Mizuguchi N; Katou F; Hashimoto K; Kawada A; Yoshie O
    J Immunol; 2010 Dec; 185(11):6472-9. PubMed ID: 20974991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of interaction between Fractalkine and CX3CR1 in cytotoxicity of natural killer cells against tumor cells.
    Zhang X; Wei H; Wang H; Tian Z
    Oncol Rep; 2006 Feb; 15(2):485-8. PubMed ID: 16391873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of natural killer cell-dependent antitumor immunity by the Autographa californica multiple nuclear polyhedrosis virus.
    Kitajima M; Abe T; Miyano-Kurosaki N; Taniguchi M; Nakayama T; Takaku H
    Mol Ther; 2008 Feb; 16(2):261-8. PubMed ID: 18059370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.
    Wei H; Zheng X; Lou D; Zhang L; Zhang R; Sun R; Tian Z
    Mol Immunol; 2005 May; 42(9):1023-31. PubMed ID: 15829292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease.
    Patel A; Jagadesham VP; Porter KE; Scott DJ; Carding SR
    Eur J Vasc Endovasc Surg; 2008 Jul; 36(1):20-7. PubMed ID: 18296082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK.
    Green SR; Han KH; Chen Y; Almazan F; Charo IF; Miller YI; Quehenberger O
    J Immunol; 2006 Jun; 176(12):7412-20. PubMed ID: 16751386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy.
    Cho D; Kim TG; Lee W; Hwang YI; Cho HI; Han H; Kwon O; Kim D; Park H; Houh D
    J Invest Dermatol; 2000 May; 114(5):928-34. PubMed ID: 10771473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice.
    Takeda K; Nakayama M; Sakaki M; Hayakawa Y; Imawari M; Ogasawara K; Okumura K; Smyth MJ
    J Leukoc Biol; 2011 Oct; 90(4):777-85. PubMed ID: 21712396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CX3CR1 deficiency attenuates imiquimod-induced psoriasis-like skin inflammation with decreased M1 macrophages.
    Morimura S; Oka T; Sugaya M; Sato S
    J Dermatol Sci; 2016 Jun; 82(3):175-88. PubMed ID: 26976687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractalkine mediates natural killer-dependent antitumor responses in vivo.
    Lavergne E; Combadière B; Bonduelle O; Iga M; Gao JL; Maho M; Boissonnas A; Murphy PM; Debré P; Combadière C
    Cancer Res; 2003 Nov; 63(21):7468-74. PubMed ID: 14612547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-γ induces aberrant CD49b⁺ NK cell recruitment through regulating CX3CL1: a novel mechanism by which IFN-γ provokes pregnancy failure.
    Li ZY; Chao HH; Liu HY; Song ZH; Li LL; Zhang YJ; Yang Y; Peng JP
    Cell Death Dis; 2014 Nov; 5(11):e1512. PubMed ID: 25375377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved.
    Wu TY; Fleischmann WR
    J Interferon Cytokine Res; 2001 Dec; 21(12):1117-27. PubMed ID: 11798470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation.
    Garcia JA; Pino PA; Mizutani M; Cardona SM; Charo IF; Ransohoff RM; Forsthuber TG; Cardona AE
    J Immunol; 2013 Aug; 191(3):1063-72. PubMed ID: 23817416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between CX3CL1 and CX3CR1 regulates vasculitis induced by immune complex deposition.
    Morimura S; Sugaya M; Sato S
    Am J Pathol; 2013 May; 182(5):1640-7. PubMed ID: 23470165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF-κB-mediated inverse regulation of fractalkine and CX3CR1 during CLP-induced sepsis.
    Raspé C; Höcherl K; Rath S; Sauvant C; Bucher M
    Cytokine; 2013 Jan; 61(1):97-103. PubMed ID: 23026294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective roles of CX3CR1-mediated signals in toxin A-induced enteritis through the induction of heme oxygenase-1 expression.
    Inui M; Ishida Y; Kimura A; Kuninaka Y; Mukaida N; Kondo T
    J Immunol; 2011 Jan; 186(1):423-31. PubMed ID: 21131421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.